Biotech Values

[DewDiligence]

From Matt Herper’s blog today:

http://www.forbes.com/sites/matthewherper/2012/07/31/the-key-question-for-dendreon-is-there-demand-for-provenge/

Provenge was once widely expected to be a blockbuster, but demand has never panned out. Since the product was launched, shortfalls have been blamed on poor reimbursement from Medicare and insurers, on trouble with the marketing message, and now on sales force issues.

It’s also possible, though, that doctors and patients just don’t find the data behind the drug appealing, and that the number of patients who can take it is more limited than anyone expected.